Form 4: Nuo Therapeutics Director Acquires Warrants

Nuo Therapeutics Director and 10% owner Scott M. Pittman acquired various warrants to purchase common stock with an exercise price of $1.50 per share.

Summary

• Scott M. Pittman, a Director and 10% Owner of Nuo Therapeutics, Inc. (AURX), acquired derivative securities (warrants) on January 23, 2026.
• The acquisition involved several tranches of warrants, totaling 74,316 underlying common stock shares.
• All acquired warrants have an exercise price of $1.50 per share and an expiration date of January 23, 2031.
• A significant portion of these warrants (36,750 shares from Origination Second and Capital Second Warrants) will vest on September 30, 2026, contingent on a 'Second Funding' event.
• An additional 7,516 shares from Prepayment Warrants will vest upon a 'Prepayment' event, but no later than December 31, 2028.
• The Board of Directors and Non-Employee Directors approved the underlying Loan and Security Agreement dated January 21, 2026, and the issuance of these warrants.

Sentiment

Score: 7

Explanation: The acquisition of warrants by a Director and 10% owner generally indicates a positive outlook from management, suggesting confidence in the company's future value. The Board's approval of the underlying Loan Agreement and warrant issuance further supports this positive sentiment, despite the contingent vesting conditions.

Positives

• A Director and 10% owner, Scott M. Pittman, acquired a substantial number of warrants, which can signal strong insider confidence in the company's future prospects and valuation.
• The Board of Directors and Non-Employee Directors formally approved the Loan Agreement and the issuance of these warrants, indicating corporate alignment with the transaction.

Risks

• The vesting of 36,750 warrants (Origination Second Warrants and Capital Second Warrants) is contingent upon a 'Second Funding' occurring by September 30, 2026, as per the Loan and Security Agreement.
• The vesting of 7,516 Prepayment Warrants is contingent upon a 'Prepayment' event, but no later than December 31, 2028, also in accordance with the Loan Agreement.
• Failure to meet these funding or prepayment conditions could result in a portion of the warrants not vesting.

Future Outlook

The vesting of a significant portion of the acquired warrants is contingent upon future events, specifically a 'Second Funding' by September 30, 2026, and a 'Prepayment' event by December 31, 2028, as outlined in the Loan and Security Agreement. This indicates future financing activities are anticipated and tied to the full realization of these equity incentives.

Management Comments

• The Board of Directors of Issuer and Non-Employee Directors approved the Loan Agreement and issuance of warrants and shares of Common Stock issuable thereunder.

Industry Context

This Form 4 reports an insider's acquisition of warrants, which is a routine disclosure for publicly traded companies. Such transactions are closely watched by investors for signals regarding management's confidence in the company's future prospects. The underlying Loan and Security Agreement suggests financing activities, which are common across industries for growth or operational needs, particularly for companies seeking capital.

Corporate Governance

Related Party Transactions

• The acquisition of warrants by Scott M. Pittman, a Director and 10% Owner, is part of a Loan and Security Agreement dated January 21, 2026, between the Issuer, the Reporting Person, and other parties, constituting a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution upon warrant exercise, but also a strong signal of insider confidence in the company's future value. The Loan Agreement could provide necessary capital for company operations or growth.
• Creditors: The Loan and Security Agreement implies new debt, which could affect the company's credit profile and leverage.

Next Steps

• Monitor for the occurrence of a 'Second Funding' event by September 30, 2026, which will trigger the vesting of certain warrants.
• Observe for a 'Prepayment' event by December 31, 2028, which will trigger the vesting of additional warrants.
• The warrants can be exercised by their expiration date of January 23, 2031.

Key Dates

Recommendation

The acquisition of warrants by a Director and 10% owner signals insider confidence in Nuo Therapeutics' future prospects, which is generally a positive indicator. However, without further details on the company's comprehensive financial performance, the full terms of the Loan and Security Agreement, and the broader market context, a 'hold' recommendation is prudent. Investors should monitor the contingent vesting conditions and the impact of the underlying financing on the company's capital structure and operational capabilities.

Keywords

Nuo Therapeutics, AURX, Scott M. Pittman, Form 4, Insider Trading, Warrants, Director, 10% Owner, Equity Acquisition, Loan Agreement